Source: ALL

Gene Disease Score gda Association Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis
0.400 GeneticVariation BEFREE A series of studies has revealed that mutations of KRAS are involved in gastric carcinogenesis. 19639197

2009

Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis
0.400 GeneticVariation BEFREE Considering the above results of PCR-SSCP and RT-PCR, genetic alterations of the p16 gene are rarely implicated in human gastric cancer tumorigenesis. 9222307

1997

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis
0.400 GeneticVariation BEFREE These results provide new insights into mutant KRAS function and its role in carcinogenesis. 23580570

2013

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis
0.400 GeneticVariation BEFREE These results suggest that (1) the K-ras and p53 gene alterations would have no special roles in terms of the lung carcinogenesis in young adults; (2) a positive relationship between smoking and p53 gene alteration would exist in young adults with lung cancer, and (3) K-ras gene alteration would become a prognostic factor in lung cancer. 7715905

1995

Entrez Id: 673
Gene Symbol: BRAF
BRAF
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis
0.400 GeneticVariation BEFREE According to the literature, our data provide evidence of the BRAF and RAS roles in thyroid tumorigenesis, supporting an association between BRAF (V600E) mutations and the more aggressive clinical and pathological features of thyroid tumors. 29435002

2018

Entrez Id: 4780
Gene Symbol: NFE2L2
NFE2L2
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis
0.400 GeneticVariation BEFREE Highlighting the importance of this pathway as a determinant of susceptibility to carcinogenesis, multiple studies now demonstrate enhanced incidence, multiplicity, and/or tumor burden in Nrf2-disrupted mice compared to wild-type in models of inflammation and colon cancer, bladder cancer, lung disease and cancer, stomach cancer, mammary cancer, skin cancer, and hepatocarcinogenesis. 21369766

2011

Entrez Id: 4780
Gene Symbol: NFE2L2
NFE2L2
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis
0.400 GeneticVariation BEFREE Compound deletion of Atg7 and Nrf2 had no additive effect, suggesting that both genes modulate tumorigenesis by regulating oxidative stress and revealing a potential mechanism of autophagy-mediated tumor suppression. 23965987

2013

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis
0.400 GeneticVariation BEFREE Bexarotene plus erlotinib suppress lung carcinogenesis independent of KRAS mutations in two clinical trials and transgenic models. 21636548

2011

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis
0.400 GeneticVariation BEFREE The presence of these mutations did not vary according to the degree of dysplasia (GNAS: invasive 61%, high-grade 59%, low-grade 53%; KRAS: invasive 71%, high-grade 62%, low-grade 74%), suggesting that mutations in these genes occur early in IPMN carcinogenesis. 25840541

2015

Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis
0.400 GeneticVariation BEFREE We investigated the role of CDKN2A deletion in urothelial carcinogenesis, as a function of FGFR3 mutation status, a marker for one of the two pathways of bladder tumour progression, the Ta pathway. 22422578

2012

Entrez Id: 673
Gene Symbol: BRAF
BRAF
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis
0.400 GeneticVariation BEFREE Disruption of the Raf/MEK/ERK (MAPK) kinase pathway, either by RAS or BRAF mutation, was detected in approximately 62% of all CC and is therefore one of the most frequent defects in cholangiocellular carcinogenesis. 12692057

2003

Entrez Id: 673
Gene Symbol: BRAF
BRAF
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis
0.400 GeneticVariation BEFREE Much lower frequencies of BRAF and PIK3CA mutations may suggest that they do not play a major role in the tumorigenesis of A-ACs. 26997442

2016

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis
0.400 GeneticVariation BEFREE These results suggest that carcinogenesis in the biliary tract epithelium in APBDU is accompanied by multistep genetic mutational events; K-ras gene mutation occurs early in epithelial hyperplasia or metaplasia, whereas inactivation of the DPC-4 gene accumulates late in the progression of biliary tract adenocarcinoma. 12720172

2003

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis
0.400 GeneticVariation BEFREE Mutations in KRAS and TP53 are common in colorectal carcinogenesis and are associated with resistance to therapy. 23456389

2013

Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis
0.400 GeneticVariation BEFREE Our data indicate that genetic variants in CDKN2A, and possibly nearby genes, may be associated with ESCC and several other tumours, further highlighting the importance of 9p21.3 genetic variants in carcinogenesis. 23361049

2013

Entrez Id: 673
Gene Symbol: BRAF
BRAF
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis
0.400 GeneticVariation BEFREE Further investigation of the CTH gene in colorectal carcinogenesis with regards to KRAS and BRAF mutations or other molecular characteristics of the tumor may be warranted. 29694444

2018

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis
0.400 GeneticVariation BEFREE The high frequency of transitions among K-RAS mutation suggests that G/T mismatches play an important role in the oncogenesis of colorectal adenocarcinoma, implying that alkylating carcinogens may be involved in the colorectal carcinogenesis. 15771905

2005

Entrez Id: 673
Gene Symbol: BRAF
BRAF
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis
0.400 GeneticVariation BEFREE Promoter hypermethylation and the BRAF(V) (600E) mutation are both involved in thyroid tumorigenesis. 25988212

2016

Entrez Id: 673
Gene Symbol: BRAF
BRAF
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis
0.400 GeneticVariation BEFREE Here we demonstrate that the expression of an endogenous Braf(D631A) kinase-inactive isoform in mice (corresponding to the human BRAF(D594A) mutation) triggers lung adenocarcinoma in vivo, indicating that BRAF-inactivating mutations are initiating events in lung oncogenesis. 28783725

2017

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis
0.400 GeneticVariation BEFREE Our results showed that the PM of K-ras gene at codon 12 was a fairly common event in genetic abnormality and suggested it would have some role in the progression of carcinogenesis in endometrial carcinoma. 8428691

1993

Entrez Id: 673
Gene Symbol: BRAF
BRAF
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis
0.400 GeneticVariation BEFREE The aim of the present study was to evaluate the methylation status of three cancer-related genes, APC2, p14ARF, and ECAD in colorectal carcinogenesis and their association with the mutational status of BRAF and KRAS among Iranian colorectal cancer patients. 21455633

2011

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis
0.400 GeneticVariation BEFREE Mutations in KRAS are initiating events in pancreatic carcinogenesis supported by genetically engineered mouse models of the disease. 29079305

2019

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis
0.400 GeneticVariation BEFREE Although epidermal growth factor receptor (EGFR)/KRAS mutation-driven lung tumorigenesis is well understood, the mechanism of EGFR/KRAS-independent signal activation remains elusive. 27593936

2017

Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis
0.400 GeneticVariation BEFREE In this aspect, the potential role of the CDKN2 gene at 9p21-p22 in ovarian carcinogenesis was assessed in an extended panel of ovarian tumors, 11 human ovarian carcinoma cell lines, and 1 cervical tumor cell line. 7743516

1995

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis
0.400 GeneticVariation BEFREE Histopathological and oncological examinations indicated that the lesions were involved in the development and progression of carcinogenesis because a point mutation of the K- ras gene and overexpression of p53 protein were detected. 12444445

2002